US-based investment bank Jefferies has downgraded its recommendation for Genmab from "buy" to "hold," as the share price has risen by around 10 percent since the start of the year and 40 percent since March, while S&P's index has fallen 9 percent since the New Year.
The brand new analysis from the bank states that a lack of short-term catalysts is another reason that it has changed its recommendation. The next big news expected from the company is the results of the extended study of Epcoritamab (CD3xCD20) for the treatment of Leukemia, which Jefferies expects to be publicized in summer 2022.
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.